Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YEG
|
|||
| Former ID |
DIB014364
|
|||
| Drug Name |
REGN-910
|
|||
| Synonyms |
SAR-3077646; Anti-angiopoietin-2 antibody (cancer), Regeneron/sanofi-aventis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2], [3] | |
| Company |
Regeneron Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin-2 (ANGPT2) | Target Info | . | [4] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | |||
| Reactome | Tie2 Signaling | |||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8457). | |||
| REF 3 | ClinicalTrials.gov (NCT01997164) Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME). U.S. National Institutes of Health. | |||
| REF 4 | Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.